We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for real-time alerts, custom portfolio, and market movers
| Name | Symbol | Market | Type |
|---|---|---|---|
| AstraZeneca PLC | NYSE:AZN | NYSE | Depository Receipt |
| Price Change | % Change | Price | High Price | Low Price | Open Price | Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 54.17 | 0 | 01:00:00 |
From May 2019 to May 2024
By Carlo Martuscelli
AstraZeneca PLC (AZN.LN) reported mixed results from a phase 3 clinical trial for its drug Farxiga, a treatment for cardiovascular disease in patients with diabetes.
The pharmaceutical major said on Monday that Farxiga didn't meet its efficacy objective of reducing major adverse cardiovascular events in a statistically significant way.
However the treatment was effective in reducing hospitalization for heart failure and cardiovascular death, the drug maker said.
AstraZeneca said it will present detailed results from the trial, called Declare, on Nov. 10.
Write to Carlo Martuscelli at carlo.martuscelli@dowjones.com
(END) Dow Jones Newswires
September 24, 2018 02:29 ET (06:29 GMT)
Copyright (c) 2018 Dow Jones & Company, Inc.
1 Year AstraZeneca Chart |
1 Month AstraZeneca Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
